Paid Clinical Trials and Focus Groups by Location |
|
|
|
Condition: Surgical Wound Dehiscence
Interventions: Device: Strattice(TM) Reconstructive Tissue Matrix; Procedure: Suture/suture with absorbable mesh
Sponsor: LifeCell
Not yet recruiting - verified March 2010
Condition: Cytomegalovirus Infection
Interventions: Biological: Adoptive Cellular Therapy; Drug: Best available antiviral drug therapy
Sponsors: Cell Medica Ltd; Wellcome Trust; Choice Pharma Ltd; Commitum AB; BioAnaLab
Recruiting - verified February 2010
Condition: Ovarian Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: taspoglutide; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Macular Degeneration
Interventions: Device: Epimacular Brachytherapy; Drug: Ranibizumab
Sponsors: King's College Hospital NHS Trust; NeoVista
Recruiting - verified February 2010
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: exenatide once weekly; Drug: insulin detemir
Sponsors: Amylin Pharmaceuticals, Inc.; Eli Lilly and Company
Recruiting - verified December 2009
Condition: Carcinoma, Hepatocellular
Interventions: Drug: BIBF 1120; Drug: BIBF 1120; Drug: Sorafenib; Drug: Sorafenib
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Cancer
Interventions: Biological: adoptive immunotherapy; Biological: alemtuzumab; Biological: in vitro-treated peripheral blood lymphocyte therapy; Drug: foscarnet sodium; Drug: ganciclovir; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: infection prophylaxis and management; Procedure: peripheral blood stem cell transplantation; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsor: University Hospital Birmingham
Recruiting - verified September 2009
Condition: Prostate Cancer
Intervention: Drug: CNTO888
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: Tiotropium 18mcg daily; Drug: Salmeterol 100mcg daily; Drug: Fluticasone 250mcg daily; Drug: Fluticasone 125mcg daily; Drug: Fluticasone 50mcg daily; Drug: Placebo
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Diabetes Mellitus, Type 2; Acute Coronary Syndrome
Interventions: Drug: Alogliptin; Drug: Placebo
Sponsor: Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: INSULIN GLARGINE (HOE901); Drug: Insulin aspart; Drug: Insulin Glulisine
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo; Drug: SRT2104
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: HIV Infections
Interventions: Drug: darunavir tablets; Drug: ritonavir capsule
Sponsors: Tibotec Pharmaceuticals, Ireland; Tibotec Pharmaceuticals
Recruiting - verified February 2010
Conditions: Anemia; Chronic Kidney Disease
Intervention: Drug: darbepoetin alfa
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Phenylketonuria
Interventions: Dietary Supplement: high oleic sunflower oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil; Dietary Supplement: microalgal oil
Sponsors: Ludwig-Maximilians - University of Munich; European Union
Recruiting - verified January 2010
Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Conditions: Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Unstable Angina
Intervention: Drug: Rivaroxaban; Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Bayer
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Placebo; Drug: Pemetrexed; Other: Best Supportive Care
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: ADHD
Interventions: Drug: SPD489 (lisdexamfetamine dimesylate); Drug: Placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-FU; Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Epilepsies, Partial
Intervention:
Sponsor: UCB, Inc.
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Exemestane + Dasatinib; Drug: Exemestane + Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: ADHD
Interventions: Drug: LDX; Drug: Methylphenidate Hydrochloride; Drug: Placebo
Sponsor: Shire Pharmaceutical Development
Recruiting - verified February 2010
Condition: Diabetic Foot Ulcer
Intervention: Drug: Fragmin
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Drug: Atomoxetine
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Type 2 Diabetes
Interventions: Drug: Saxagliptin; Drug: Placebo
Sponsors: Bristol-Myers Squibb; AstraZeneca
Recruiting - verified October 2009
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Diabetes Mellitus
Interventions: Drug: Exubera; Other: Randomized diabetes therapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Condition: Acute Coronary Syndrome
Interventions: Drug: Clopidogrel; Drug: Prasugrel; Drug: Commercially-available Aspirin
Sponsors: Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Duke University
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Diabetic Macular Edema
Interventions: Drug: Choline Fenofibrate; Drug: Placebo
Sponsor: Solvay Pharmaceuticals
Recruiting - verified March 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: HIV-1
Intervention: Drug: TMC125
Sponsor: Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010
Condition: Diabetic Foot Ulcer
Interventions: Drug: Fragmin/ Dalteparin Sodium; Drug: Placebo for Fragmin/ Dalteparin Sodium
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Coronary Heart Disease
Interventions: Drug: dalcetrapib; Drug: Placebo; Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor: Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Myocardial Infarction
Interventions: Drug: tenecteplase; Drug: enoxaparin; Drug: clopidogrel; Procedure: catheterisation; Procedure: primary PCI
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Sepsis
Interventions: Drug: Drotrecogin alfa (activated); Drug: Placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Procedure: quality-of-life assessment; Procedure: questionnaire administration
Sponsor: University of Birmingham
Recruiting - verified February 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: Temsirolimus; Drug: Sorafenib
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Pain, Postoperative
Interventions: Drug: pregabalin (Lyrica); Drug: pregabalin (Lyrica); Drug: matched placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Cytomegalovirus Infections
Interventions: Drug: Placebo; Drug: Valganciclovir
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified October 2009
Condition: Leukemia, Lymphocytic, Chronic
Intervention: Drug: alvocidib (HMR1275)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Hepatitis B, Chronic
Intervention: Drug: Entecavir
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Atrial Fibrillation; Atrial Flutter
Interventions: Drug: warfarin; Drug: apixaban
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Glioma; Medulloblastoma
Interventions: Drug: Irinotecan; Drug: Temozolomide
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Heart Failure; Anemia; Cardiovascular Disease; Ventricular Dysfunction; Congestive Heart Failure
Interventions: Drug: Darbepoetin alfa; Drug: Placebo
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010